Introduction
The Struma ovarii is a rare ovarian tumor, representing 0.5-1% of all ovarian tumors and 2-5% of ovarian teratomas [1] , that has been first described by Von Klden in 1895, followed by Gottschalk in 1899 [2] . It can occur in females of all ages, although with a predilection for women in their fifth and sixth decade of life [3] . It is defined as an ovarian teratoma composed mostly of thyroid tissue, occupying more than 50% of the ovarian mass. They are usually benign, although 5-10% of all cases are malignant, with the most common histological type being the papillary thyroid carcinoma (70%), and does not usually lead to metastatic disease (5-6%). [3, 4] . When metastasis does occur, the struma ovarii behaves in a way similar to other primary ovarian cancer. In other words, it tends to cause peritoneal carcinomatosis, also affecting the contralateral adnexa and/or epiplon. It can either present a lymphatic or haematogenous dissemination, spreading to pelvic/paraaortic lymph nodes or bone, liver and brain respectively [5] .
The symptoms of the Struma ovarii are similar to those described in other ovarian tumors, and also tend to be nonspecific (abdominal pain, abnormal menstrual cycles and vaginal bleeding) [6] . Thyroid dysregulation symptoms, such as hyperthyroidism, are rare, occurring only 5-8% of the cases. [7, 8] . The imaging studies can help characterize the mass; however, the definitive diagnosis is given by the Pathologist.
Classically, the definitive treatment is the surgical resection of the ovarian cyst, however there is no consensus among practitioners regarding the follow-up. The adjuvant use of radioactive Iodine-131 in malignant struma ovarii remains controversial due to the scarcity of information and the lack of significant prospective studies, and is usually employed to treat recurrences and metastasized disease. According to the various studies, the management of the struma ovarii, following the removal of the pelvic mass, is individualized, depending on the patient and the medical team. [9, 10] . We report a case of an asymptomatic malignant struma ovarii in a 43 year-old patient diagnosed postoperatively following a laparoscopic adnexectomy due to an apparently benign ovarian teratoma and its management. This work has been done in line with the SCARE criteria [11] .
Clinical case description
An ovarian mass was detected in an asymptomatic 43 yearold women, TPAL 2002, with no relevant familial or personal antecedents, in a routine gynecological check up. The preoperative ultrasound revealed no apparent signs of malignancy, and was described as a 7 cm solid solid-cystic mass compatible with cystic teratoma. The basal tumor markers were as follows: CEA 3.0 ng/ml; AFP 1.5 ng/ml; CA 125 17.9 UI/ml; CA 153 11.9 UI/ml; CA 199 91.8 UI/ml. The patient underwent a scheduled laparoscopic left adnexectomy with no incidents, and the mass was sent to pathology for analysis. There were no other pathological findings during laparoscopic exploration. The histopathology results revealed a « mature ovarian cystic teratoma with papillary carcinoma with immunohistochemical characteristics suggesting a thyroid origin (positive TTF-1, uncertain positive for thyroglobulin stain) (Figs. 1-4) . Following these results, the patient was referred simultaneously to the gynecological-oncology and endocrinology consults for further studying. The diagnostic 131 I scintigraphy revealed a normal pattern of thyroid uptake and the thyroid ultrasound was normal. The stimulated serum thyroglobulin, and antimicrosomal antibodies levels were also normal.
Upon seeing that the rest of the results were negative, we decided on maintaining a conservative management with a gynecological, with high resolution gynecological ultrasounds, and endocrinology controls every 6 months during the first year fol- lowing the diagnosis. A yearly follow-up with an annual Thoracic abdominopelvic CT scan and tumor markers (CEA, CA125, CA153, BHCG) were performed. The endocrinology department also performed annual checkups with thyroid ultrasound and serum panels (thyroglobulin, free T4, T3, TSH). The patient is currently 47 yearsold, and has remained asymptomatic during these last four years, with no signs of relapse or thyroid affectation. 
Discussion
There is little evidence in literature on the conservative management in cases with evidence of malignancy. In cases of fertility preservation, a unilateral salpingo-oophorectomy could be performed, along with levels of serum thyroglobulin as a marker of relapse. In our case, a unilateral salpingo-oophorectomy was performed, not for fertility preservation, but because the mass was considered to be benign, nevertheless an endobag was used for the retrieval of the specimen as we usually do in suspicious adnexal masses and the patient consented only to a unilateral procedure. Some authors, especially in patients with no need for fertility preservation, claim that the cases of malignant struma ovarii requires an ovarian cancer surgical staging with pelvic washings, total hysterectomy with double adnexectomy and lymphadenectomy, as well as a total thyroidectomy followed by 131 I radioablation, which would allow us to obtain the histological confirmation that the struma is of ovarian origin and prevent recurrences [12] .
On the other hand, other authors consider that pelvic surgery is sufficient in patients with thyroid cancer confined to the ovary, and do not recommend prophylactic thyroidectomy and/or 131 I radioablation. [13] . The management of thyroid nodules in these patients varies as well, including regular checkups with ultrasound and thyroglobulin levels or a total thyroidectomy with or without 131 I radioablation therapy postoperatively [14, 15] .
In conclusion, there is still no established treatment algorithm for struma ovarii patients and the choice for a conservative or radical approach depends solely on the Professional in charge of the patient. There is a need for multicentric studies and further research in order to resolve the treatment and management dilemma.
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